Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

Inclusion Criteria:

• Provision of written informed consent

• Male or female (sex at birth) aged ≥18 years

• Diagnosis of AAE-C1INH

• History of AAE-C1INH attacks prior to the Screening Visit:

• Participants enrolling in Part 1 must have stable underlying disease of AAE-C1INH

• The underlying condition can reasonably be expected to remain stable for theduration

• Reliable access and ability to use available therapy to effectively manage AAE-C1INH attacks.

• Female participants of childbearing potential must agree to the protocol-specifiedpregnancy testing and to be abstinent from heterosexual intercourse or to use anacceptable contraception method.

Females of non-childbearing potential (prepubertal, surgically sterile, or postmenopausal with ≥ 12 months amenorrhea and postmenopausal FSH confirmation) are not required to use contraception during the study.

• Capable of recording, without assistance, eDiary and ePRO data using an electronic device, as evidenced by the eDiary and ePRO training.

Exclusion Criteria:

• Participation in a clinical study with any other investigational drug within thelast 30 days or within 5 half-lives of the investigational drug at the ScreeningVisit (whichever is longer).

• Participants who have previously received prophylactic therapy but have stopped canparticipate in this study provided the last dose of the treatment was received priorto the timepoint before the Screening Visit

• Any females who are pregnant, plan to become pregnant, or are currentlybreast-feeding

• Abnormal hepatic function

• Moderate or severe renal impairment

• Any clinically significant comorbidity or systemic dysfunction that would interferewith the participant's safety or ability to participate in the study.

• History of epilepsy and/or other significant neurological diseases

• Any clinically significant and uncontrolled gastrointestinal dysfunction that mayimpact study drug absorption

• Evidence of current alcohol or drug abuse

• Use of medications that are moderate and strong inhibitors of cytochrome P450 (CYP) 3A4, or strong inducers of CYP3A4 within the last 30 days or within 5 half-lives (whichever is longer) at the time of the Screening Visit

• Known hypersensitivity to deucrictibant or any of the excipients of the study drug

• Use of angiotensin-converting enzyme inhibitors or any estrogen-containingmedications